Angle (AGL)

 

Latest News

Preclinical Study Presented At Tumor Boston Summit

RNS Number: 6533L Angle PLC 20 July 2017 For immediate release 20 July 2017 ANGLE plc ("the Company") PRECLINICAL STUDY USING PARSORTIX PRESENTED AT TUMOR MODELS BOSTON SUMMIT Parsortix system demonstrates capabilities for use in cancer drug research ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy co...

Notice of Results

RNS Number: 3024K Angle PLC 06 July 2017 For Immediate Release 6 July 2017 ANGLE plc ("ANGLE" or "the Company") Notification of Preliminary Results and Webcast ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 30 April 2017 on Thursday 27 July 2017. A meeting...

ANGLE confirms successful data in cancer studies

ANGLE , a world-leading liquid biopsy company, has announced positive headline results from 400 patient pelvic mass stu...

Successful Headline Data in Ovarian Cancer Studies

RNS Number: 0003K Angle PLC 04 July 2017 For immediate release 4 July 2017 ANGLE plc ("the Company") ANGLE REPORTS SUCCESSFUL HEADLINE DATA IN US AND EUROPEAN OVARIAN CANCER STUDIES IN 400 PATIENTS Parsortix blood test demonstrates potential to out-perform current standard of care in identifying ovarian cancer ANGL...

All News

DateHeadlineSource
20-07-17Preclinical Study Presented At Tumor Boston SummitRNS
06-07-17Notice of ResultsRNS
04-07-17ANGLE confirms successful data in cancer studies StockMarketWire
04-07-17Successful Headline Data in Ovarian Cancer StudiesRNS
15-06-17FTSE lower amid ex-divs ahead of BoE rate callStockMarketWire
15-06-17Parsortix breakthrough in prostate cancerRNS
05-06-17Parsortix success reported at ASCO, says ANGLE StockMarketWire
05-06-17Success with Parsortix in Colorectal CancerRNS
03-05-17Business UpdateRNS
04-04-17Holding(s) in CompanyRNS
03-04-17Parsortix enables analysis in head and neck cancerRNS
30-03-17Prostate Cancer UpdateRNS
13-02-17Selected for European Cancer ID ProgrammeRNS
26-01-17Interim Evaluation of Ovarian Cancer StudyRNS
26-01-17Interim ResultsRNS
06-01-17ANGLE Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017StockMarketWire
04-01-17ANGLE schedules interims StockMarketWire
04-01-17Notice of ResultsRNS
29-12-16Our AIM tip soars 60% in 2016 Interactive Investor
28-11-16ISSUE OF SHARE OPTIONSRNS
24-11-16Result of GMRNS
04-11-16ANGLE welcomes new research supporting Parsortix StockMarketWire
04-11-16Barts Research Supports Potential Use of ParsortixRNS
01-11-16Notice of GMRNS
27-10-16Director's share purchaseRNS
07-10-16Holding(s) in CompanyRNS
04-10-16Result of AGMRNS
30-09-16ANGLE notes research results in Clinical ChemistryStockMarketWire
30-09-16Research published in Clinical ChemistryRNS
19-09-16Issue of EquityRNS
09-09-16Annual Report and Accounts and Notice of AGMRNS
04-08-16MD Anderson Cancer Center poster presentationRNS
02-08-16Edison issues ADR update on AngleRNS
28-07-16ANGLE revenue upStockMarketWire
28-07-16Use of Parsortix in GANNET53 drug trialRNS
28-07-16Preliminary ResultsRNS
27-07-16ANGLE initiates ovarian cancer study in the USStockMarketWire
27-07-16Initiation of 200 patient US ovarian cancer studyRNS
19-07-16ANGLE initiates European ovarian cancer study StockMarketWire
19-07-16Initiation of European ovarian cancer studyRNS

RSS feeds

  • Editorial news feed for LSE:AGL Editorial
  • Regulatory news feed for LSE:AGL Regulatory